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Although pharmacogenomics (PGx) offers the promise of ensuring the right patient receives the right medication at the right dose the first time, gene-drug interaction data have yet to be seamlessly integrated into patients' health records. PGx testing that is preemptive, adaptable, current, and executable (PACE) overcomes the human and technological barriers to successful implementation, thus capitalizing on the affordable cost of such testing and clinical practice guidelines at the point of prescription ordering.
VALUE OF PGX IN CLINICAL PRACTICE
The term PGx, or the study of how genes affect a person's response to drugs, was first introduced in the 1950s by Friedrich Vogel. 1 During the past decade, technological advances have led to lowcost genotyping and sequencing platforms, allowing scale and test affordability. Patient samples obtained through a simple buccal swab DNA are screened for variants in drug-metabolizing enzymes linked to extreme phenotype classifications-ultrarapid or poor metabolizers-that predispose a patient to adverse drug events or a lack of drug efficacy. Although this information is important for the treatment of patients with specific diseases, population studies now indicate most individuals stand to benefit from PGx testing. In a recent study of 1013 subjects, 99% of participants carry an actionable variant of the five pharmacogenes tested. 2 This observation implies that virtually every person metabolizes and responds to drugs differently, a finding with significant impact whether an individual currently takes medications or will do so in the future. Despite such evidence and the reasonable cost of clinical PGx testing, a lack of practitioner engagement and the challenge of integrating PGx information into the electronic health record have hindered implementation into routine medical practice.
DEVELOPMENT OF PGX CLINICAL PRACTICE GUIDELINES
To systematically implement PGx in the clinical practice, the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) develop peer-reviewed guidelines on how to best apply genetic data to optimize drug therapy. On the basis of the work of CPIC, DPWG, and other professional societies, the Pharmacogenomics Knowledgebase (PharmGKB) curates and disseminates information on 100 dosing guidelines via its website.
To translate PGx recommendations into the clinical electronic environment, CPIC launched an Informatics Working Group in 2013. Since then, the group has worked to develop resources for integrating PGx into electronic health records with clinical decision support. 3, 4 Such resources are essential for clinical implementation, given electronic health record vendors do not supply clinical decision support functions for PGx. 3 
ELEMENTS FOR SUCCESSFUL IMPLEMENTATION OF PGX INTO PRACTICE
The clinical application of PGx testing has not been disseminated into the routine practice of medicine, despite the test's value, current affordability, and existence of published clinical practice guidelines. To improve implementation, we propose that the clinical application of PGx be PACE (Figure 1 ).
Preemptive
The value of preemptive PGx testing, performed and entered in a patient's electronic health record before actual use, is that it ensures seamless integration at the point of care. At the present time, PGx testing costs have become comparable to other routine blood testing, 5 thus justifying its use in a preemptive manner. Thereafter, the patient and healthcare providers would be aware of potential genedrug adverse reactions during future clinical encounters. Preemptive testing would also alleviate any undue delays in treatment that may occur if PGx testing is ordered when starting a new medication.
Implementation of preemptive testing may be predicated on available local resources and expertise. For instance, large medical centers may have the resources to accommodate all comers, offering preemptive testing to every patient. In the case of small hospitals without that ability, preemptive testing could be offered on the basis of the needs of patient populations served. For example, resources and expertise may be available to perform PGx on high-yield cardiovascular or psychiatric patients. Such an approach would make preemptive, but more focused, PGx testing doable for most hospitals. Large-scale research studies designed to validate the importance of preemptive PGx testing and related drug-gene interactions are currently underway. For example, 10,000 participants of the Mayo Clinic biobank are enrolled in a study to determine the impact of PGx results in a preemptive manner. The PGx test results of these participants will be incorporated into their respective electronic health records, with providers becoming aware of the testing as an educational and drug decision tool at the point of care. PGx information falls under the umbrella of the Genetic Information Nondiscrimination Act of 2008, a federal law that protects individuals from genetic discrimination in health insurance and employment. As we develop experiences in the preemptive space, they may provide the results needed to prove the benefit of and cost-cutting effects of preemptive testing to health insurers.
Adaptable
As medical care is offered across diverse settings-from hospitals and outpatient facilities to community pharmacies and those providing drugs for hospice or home care as well as for patients benefiting from connected care or telemedicine-PGx testing must be adaptable to meet the needs of patients and healthcare providers throughout a variety of medical practices and care systems.
For example, primary care practitioners may opt for a PGx testing product that includes a few pharmacogenes (i.e., SLCO1B1 and HLA-B*5801) focused on predicting significant adverse drug reactions (i.e., myopathy attributable to statins for associated SLCO1B1 variants or severe skin disease attributable to allopurinol, a drug commonly used to treat gout for HLA-B*5801-positive individuals), in which interpretation of findings is straightforward. In contrast, a hospital pharmacist may have more specific needs that require a comprehensive PGx testing panel to serve the medical therapy of his or her patients. Although a comprehensive test for inpatient and outpatient settings would be ideal from a scale standpoint, in the immediate future, the extent of PGx testing in different practices will be dictated by availability of prompt interpretation as well as practitioner education and comfort discussing results. 
Current
As part of the ever-changing field of medicine, PGx testing must be current as new gene-drug information becomes available and incorporated in published clinical guidelines. At this time, several PGx testing platforms include multiple genes, which contribute to the metabolism of ≈200 of the most common medications. As such, it is essential that new data are disseminated through guidelines to reach clinicians. Toward that end, PGx testing outputs must be updated in a systematic manner and on a continual basis, in the context of the newly acquired knowledge. Keeping PGx reporting current will allow for incorporating other factors, such as drugdrug interactions, diet, and environment, into future analyses.
Executable
Despite recent progress, making PGx testing executable in daily medical practice remains a challenge. Successful execution requires both human (i.e., healthcare providers) and technical (i.e., information technology and clinical decision support tools) means. To this end, it is critical to continue to engage and educate healthcare providers on the value of applying PGx to the clinical practice. For instance, the American Board of Colleges of Pharmacy (ABCP) now requires PGx education as part of its accreditation standards, yet physicians and other healthcare providers report a lack of confidence in discussing pharmacogenomic information or testing with patients. 1 To this extent, continuing to educate practitioners will be critical because only a small percentage will be early adapters that feel comfortable integrating PGx data into practice. 1 In addition, practitioners may feel more empowered and comfortable testing patients for PGx if the dynamic test report moves through their electronic space via their usual workflow, in a visual manner that is easily interpretable for common situations without the need for expert consultation (e.g., pharmacists). Instead of developing parallel systems, processes must be created that truly integrate PGx into the practitioner's existing methods. Healthcare providers, who will not have the time to go back and look for PGx information before deciding on a prescription, will need information to be readily accessible in the electronic health record. For example, incorporating PGx into the decision-making process to change medication can be overwhelming and makes practitioners less willing to adopt. To overcome this barrier, automated systems that integrate PGx test results from electronic health records and issue interruptive alerts when a practitioner should make an adjustment to medication are being developed. Tailoring these systems to maximize the effectiveness of alerts without a practitioner becoming bombarded by them to the point of alert fatigue 4 will further aid integration.
At this time, a few academic institutions and commercial entities are currently working to develop systems capable of integrating drug-gene interactions into patient care using PGx testing. For example, PGx testing results at Mayo Clinic are reported in three "bins" as drug metabolism falls in separate categories of significance: (i) green bin (no need to change drug dose); (ii) yellow bin (need to change drug doses); and (iii) red bin (dangerous if taken). In this example, medications categorized as red function much like an allergic reaction, meaning for this specific patient the medication has to be treated differently (i.e., use with serious caution or avoid use).
Although a patient with a known, severe allergy will wear an aluminum bracelet to communicate the danger, no such universal warning system currently exists for "red bin" PGx results. Fragmented healthcare delivery systems with limited electronic health record interoperability 3 compound the problem. For example, a specialty hospital may know of the danger a certain drug poses to a patient based on his or her PGx profile, but if the patient's local hospital does not have this information, the patient will not benefit from the information unless he or she is able to convey it. As such, implementing PGx at the national level may require novel technology that enables at-risk patients to carry PGx warnings with them on their cell telephones. Such applications would need to integrate with prescribing systems of various providers.
The proposed approach does not discount the importance and need for PGx-trained pharmacists to handle complex PGx results as well as concurrent drug-drug interactions. Rather, it offers a direct opportunity for healthcare providers to use and engage with PGx testing as they would the report of a common blood test, such as, complete blood cell count.
